Physician profile
Usama Gergis
NPI 1548450984
$1,163,421.14
in general payments reported to CMS, 2019-2025
23 companies · $224K in 2025
The $224K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270K · 2020: $94K · 2021: $99K · 2022: $184K · 2023: $167K · 2024: $125K · 2025: $224K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $397K · Travel and Lodging: $68K · Consulting Fee: $34K · Food and Beverage: $11K · Honoraria: $5,730 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $397,373.75 |
| Travel and Lodging | $68,483.56 |
| Consulting Fee | $34,074.50 |
| Food and Beverage | $11,103.42 |
| Honoraria | $5,730.00 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $444,119.63 | 2019-2025 | Niktimvo, Jakafi, Jakafi |
| Jazz Pharmaceuticals INC. | $275,640.46 | 2019-2025 | |
| Astellas Pharma US INC | $199,899.25 | 2019-2025 | Xospata |
| Kite Pharma, INC. | $191,140.68 | 2019-2025 | Yescarta |
| Merck Sharp & Dohme LLC | $28,153.47 | 2019-2025 | Prevymis |
| E.R. Squibb & Sons, L.L.C. | $7,265.95 | 2023-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $5,480.63 | 2019-2024 | Kymriah |
| Autolus INC | $5,391.04 | 2025 | |
| National Marrow Donor Program | $3,400.00 | 2022-2025 | |
| Gamida Cell INC. | $1,826.78 | 2023-2025 | Omisirge |
| Celgene Corporation | $303.55 | 2019-2025 | |
| Abbvie INC. | $143.76 | 2025 | |
| Stemline Therapeutics INC. | $125.46 | 2023 | Orserdu |
| Iovance Biotherapeutics, INC. | $122.74 | 2025 | Amtagvi |
| Biolinerx USA, INC. | $119.09 | 2024 | Aphexda |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kadmon Pharmaceuticals LLC | $78.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.93 | 2019 | |
| Pfizer INC. | $57.62 | 2019 | |
| Legend Biotech USA INC. | $45.40 | 2024 | |
| Eusa Pharma (US) LLC | $19.64 | 2019 | |
| Janssen Biotech, INC. | $14.38 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $12.69 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usama Gergis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.